Jiangsu Co. Ltd. announced in relation to, among other things, the continuing connected transactions contemplated under the 2023 Manufacturing Services Agreement. In anticipation of the increase in orders for the Selected Generic Drugs for the years ending 31 March 2025 and 31 March 2026, the directors of Jacobson and JBM envisage that the Existing Annual Caps will not be sufficient.

Therefore, with effect from 2 April 2024, the Existing Annual Caps have been revised and increased to the Revised Annual Caps. 2023 Manufacturing Services Agreement. The principal terms of the 2023 Manufacturing Services Agreement remain unchanged, a summary of which is set out below: Date, 3 March 2023, Parties, (1), JBM (on behalf of its subsidiaries), (2), Jacobson (on behalf of its subsidiary), Subject, The JBM Group agreed to provide, among other things, manufacturing services of the Selected Generic Drugs to the Jacobson Group, pursuant to the terms of the 2023 Manufacturing services Agreement.

The directors of Jacobson and JB have considered the following and agreed on the Revised Annual Caps for the manufacturing of Selected Generic Drugs under the 2023 Manufacturing Services agreement as below: Historical transaction amounts for the manufacturing of Selected generic Drugs. The following table sets forth the actual services fees paid by the Jacobson Group to the JBM Group for the manufacturing of Selected generic drugs under the 2021 Manufacturing Services Agreement and the 2023 Manufacturing Services Agreement for the periods indicated: Historical transaction amount (HKD'000) For the year ended 31 March, 2022, 2023, 2024, Actual services fees (approximate), 1,956, 2,342, 3,390 (Note: As at the date of this joint announcement, based on Jacobson's and JBM's unaudited management accounts and operational data, the actual services fees for the manufacturing of Selected Generic drugs for the year ended 31 March 2024 under the 2023 Manufacturing Servicesreement have not exceeded the annual cap for the year ended 31 March 2022. However, due to existing product registration and manufacturing license arrangements, and the intention to utilise available production capacity, production of the Selected Generic Drugs has remained under the Ho Chai Kung business, which is now part of the JBM Group.

This arrangement was being formalised under the 2021 Manufacturing Services Agreement as continuing connected transactions. In anticipation of the increase In anticipation of the increase in order for the years ending 31 March 2022 and 31 March 2026, and considering that the pricing of manufacturing services under the 2023 manufacturing Services Agreement will be determined on normal commercial terms comparable to those offered to, or quoted by independent third parties, the directors of Jacobson & JBM (including the independent non-executive directors of Jacobson andJBM) view the transactions under the 2023 Manufacturing Services agreements as being on normal commercial terms or better, within the ordinary business scope of the Jacobson and JBM Groups. Both Jacobson and JBM have adopted the following internal control and corporate governance measures to ensure that the transactions contemplated under the 2023 manufacturing Services agreement will be conducted on normal commercial terms and in accordance with its terms: (i) the audit committee of both Jacobson and JBM will be reviewing and evaluating the terms of the 2023 manufacturing Services Agreement for the continuing connected transactions, in particular the pricing principles and annual caps, to ensure that such terms are fair and reasonable to the corresponding group and in compliance with the Listing Rules; (ii) the directors (including the independent non- executive directors) of both Jacobson and JB will be able to seek independent professional advice in respect of the continuing connected transactions from external professional parties in appropriate circumstances; (iii) the various internal departments (including but not limited to the finance and accounting department, sales department and production department) of both Jacobson andJBM will regularly monitor the implementation of the continuing connected transactions and keep track of the aggregate transaction amounts under the relevant agreements to ensure that the pricing principles and annual caps contained therein are complied with; (iv) both Jacobson and JBM have adoption relevant reporting and record-keeping procedures to allow their respective independent non-executive directors and auditors to perform annual review of the continuing connected transactions (including the Listing Rules; and provide annual confirmations in accordance with the Listing Rules; and provides annual confirmations in accordance with The Listing Rules; and provide Annual confirmations in accordance with the listing Rules; and provide annual confirmed in accordance with the Listing rules; and provide annual confirmations.